Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- AI-Assisted Colonoscopy and the Diminutive Adenoma Dilemma (Los Angeles Times)
- BE Surveillance, Outpatient ESD, and More (GI & Endoscopy News)
- HHS-OIG Issues Favorable Advisory Opinion for Free Multi-Cancer Detection Supplemental Reports Provided with Medicare-Covered Colorectal Cancer Screening Tests (The National Law Review)
- Physician–researcher’s work yields landmark five-year data for Crohn’s disease drug (Medical Xpress)
- CU Anschutz Biobank Partners with Tech Company to Advance Gut Research and Patient Care (The Regents of the University of Colorado)
- Novant Health adds leading gastroenterology clinicians to its Lowcountry network (Novant Health)
- Solutions Emerging for Post-GLP-1 Weight Regain (Medscape)
- CMS Grants Medicare Coverage for ColoSense®, Expanding Access to Simplified Noninvasive Colorectal Cancer Screening (Business Wire)
